CureVac (NASDAQ:CVAC) Trading 9.1% Higher – Still a Buy?

CureVac (NASDAQ:CVAC)’s stock price rose 9.1% on Tuesday . The stock traded as high as $3.12 and last traded at $3.19. Approximately 481,439 shares were traded during trading, a decline of 46% from the average daily volume of 885,243 shares. The stock had previously closed at $2.92.

Analyst Upgrades and Downgrades

Separately, JMP Securities restated a “market outperform” rating and set a $16.00 price objective on shares of CureVac in a research report on Friday, February 14th.

CureVac Trading Down 4.4 %

The firm has a market capitalization of $678.36 million, a PE ratio of 5.51 and a beta of 2.53. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. The company has a fifty day moving average of $3.64 and a 200-day moving average of $3.20.

Institutional Investors Weigh In On CureVac

Hedge funds and other institutional investors have recently made changes to their positions in the company. Integrated Wealth Concepts LLC acquired a new position in CureVac in the third quarter worth approximately $35,000. Two Sigma Advisers LP acquired a new position in shares of CureVac during the 4th quarter worth $48,000. Jump Financial LLC bought a new position in shares of CureVac during the 4th quarter valued at $55,000. D. E. Shaw & Co. Inc. bought a new position in shares of CureVac during the 4th quarter valued at $66,000. Finally, Barclays PLC acquired a new stake in shares of CureVac in the 3rd quarter valued at $67,000. 17.26% of the stock is owned by hedge funds and other institutional investors.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.